I am a Healthcare Professional outside the US and UK

I am a Healthcare Professional outside the US and UK

Click here for international medical scientific information about Oncology for Healthcare Professionals.

I am not a Healthcare Professional and I am outside the US and the UK

I am not a Healthcare Professional and I am outside the US and the UK

Click here for general international information for patients, caregivers and the general public.

Country-specific medical scientific information

Country-specific medical scientific information

Country-specific medical scientific information for Healthcare Professionals.

This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Information

InOncology.com
Welcome to
InOncology.com

A knowledge hub developed to provide information and education in oncology for healthcare professionals.

Rate this
Brain Metastases

Treatment options for EGFRm+ NSCLC patients with brain metastases

Watch this video from Maximilian Hochmair considering EGFR TKI treatment approaches for this patient population

Spotlight on Real-world Evidence

Why it matters and what it tells us about Afatinib*

NSCLC in focus: information and educational resources

Investigational compounds: their MoA and clinical development

GioTag study: Real-world data on sequential EGFR TKI treatment

View more information on this real-world study of sequential therapy with first-line afatinib followed by osimertinib in EGFRm+ NSCLC

Treatment sequencing in EGFRM+ NSCLC

Learn more about sequencing of EGFR TKIs in this latest video with Nicolas Girard

Download Library resources

Browse freely available educational materials in our Download Library, including slide decks

inOncology Article Library

Search this library for published papers about afatinib and nintedanib**

Physicians’ insights
Treatment sequencing in EGFR-mutated NSCLC

Learn more about first-line afatinib followed by osimertinib in this video with Dr Maximilian Hochmair

FIND OUT MORE
EGFR TKIs in patients with uncommon EGFR mutations

Watch as Dr Edward Kim considers which EGFR TKI to use in patients with uncommon EGFR mutations

FIND OUT MORE
EGFR TKIs for patients with squamous NSCLC

Dr David Gandara considers data on use of EGFR TKIs in squamous NSCLC

FIND OUT MORE
EGFR TKIs and brain metastases in EGFR-mutated NSCLC

Dr Noemi Reguart considers the differing intracranial activity of available EGFR TKIs

FIND OUT MORE
<
>

*Afatinib is approved in more than 80 markets, including the EU, Japan, Taiwan and Canada under the brand name GIOTRIF®, in the US under the brand name GILOTRIF® and in India under the brand name Xovoltib®; for the full list, please click here. Registration conditions differ internationally; please refer to locally approved prescribing information.

**Nintedanib is approved in the EU under the brand name VARGATEF® for use in combination with docetaxel in adult patients with locally advanced, metastatic or locally recurrent NSCLC of adenocarcinoma tumour histology after first-line chemotherapy. For the full list of country-specific information, please click here. Nintedanib is not approved in other oncology indications.